Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Syndax Pharmaceuticals
400 Totten Pond Road, Suite 140
Waltham, MA 02451
Phone: 781-419-1400
www.syndax.com

Syndax is focused on employing epigenetic strategies to overcome the problem of resistance in oncology care in solid tumors. The company holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. A randomized, placebo-controlled Phase 2 study of entinostat in combination with aromatase inhibitors in breast cancer (ENCORE 301) demonstrated an improvement in both progression-free survival and overall survival, providing the basis for the evaluation of entinostat in pivotal Phase 3 testing in metastatic breast cancer.

Key Contact
Name
Arlene M. Morris
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
08/27/13 $26,600,000 Series B Domain Associates
Forward Ventures
MPM Capital
RusnanoMedInvest
undisclosed
08/25/15 $80,000,000 Series C Arrowpoint Partners
BioMed Ventures
Cormorant Asset Management
Delos Capital Fund LP
Domain Associates
EcoR1 Capital
Fidelity Management & Research Company
Jennison Associates
MPM Capital
OrbiMed Advisors
RusnanoMedInvest
undisclosed